Lineage Cell Therapeutics, Inc.

NYSEAM:LCTX Stock Report

Market Cap: US$331.6m

Lineage Cell Therapeutics Future Growth

Future criteria checks 5/6

Lineage Cell Therapeutics is forecast to grow earnings and revenue by 72.3% and 62% per annum respectively while EPS is expected to grow by 68.8% per annum.

Key information

72.3%

Earnings growth rate

68.82%

EPS growth rate

Biotechs earnings growth25.4%
Revenue growth rate62.0%
Future return on equityn/a
Analyst coverage

Good

Last updated21 May 2026

Recent future growth updates

Recent updates

New Narrative • May 23

Cell Therapy Manufacturing And Partner Dependence Will Pressure Margins Yet Leave Long Runway

Catalysts About Lineage Cell Therapeutics Lineage Cell Therapeutics develops allogeneic cell therapies using its AlloSCOPE manufacturing platform for conditions linked to loss of specific cell function. What are the underlying business or industry changes driving this perspective?
Narrative Update • Apr 29

LCTX: AlloSCOPE Platform Progress Will Support Future Pipeline Monetization Potential

Analysts have raised their price target on Lineage Cell Therapeutics by $1, citing updated assumptions for fair value, discount rate, revenue growth, profit margin, and future P/E that reflect recent bullish coverage and target revisions from the Street. Analyst Commentary Bullish Takeaways Bullish analysts point to recent target revisions as support for a higher fair value, suggesting that prior assumptions for revenue growth, profit margins, and future P/E were conservative.
Narrative Update • Aug 06

Aging Trends And Regenerative Medicine Will Open New Avenues

Lineage Cell Therapeutics' higher net profit margin and a slight increase in its discount rate have contributed to a raised consensus analyst price target, now at $4.17. What's in the News First-ever chronic spinal cord injury patient treated in Lineage's DOSED clinical study, which evaluates a novel device for delivering OPC1 cells directly to injury sites; OPC1 has received RMAT and Orphan Drug designations from the FDA.
User avatar
New Narrative • May 18

Advancements In OpRegen And Genentech Collaborations Will Unlock Potential

Strong data support and partnership expansions, especially for OpRegen, could significantly enhance future revenue and market share in dry AMD.

Earnings and Revenue Growth Forecasts

NYSEAM:LCTX - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20286074-336
12/31/202718-32-9-317
12/31/202618-24-9-297
3/31/202615-64-23-22N/A
12/31/202515-64-19-19N/A
9/30/202511-68-21-20N/A
6/30/202511-41-23-23N/A
3/31/202510-16-23-22N/A
12/31/20249-19-24-23N/A
9/30/20249-20-23-23N/A
6/30/20246-24-22-22N/A
3/31/20248-24-24-23N/A
12/31/20239-21-29-29N/A
9/30/20239-23-31-31N/A
6/30/202311-22-32-31N/A
3/31/202312-24-33-32N/A
12/31/202215-2611N/A
9/30/202214-4933N/A
6/30/202213-5144N/A
3/31/20229-4956N/A
12/31/20214-43-24-24N/A
9/30/20214-12-24-23N/A
6/30/20212-12-24-23N/A
3/31/20212-14-22-22N/A
12/31/20202-21-20-20N/A
9/30/20203-27-20-20N/A
6/30/20203-36-22-22N/A
3/31/20203-59-28-28N/A
12/31/20194-12N/A-32N/A
9/30/20193-52N/A-32N/A
6/30/2019331N/A-32N/A
3/31/2019557N/A-30N/A
12/31/20185-46N/A-31N/A
9/30/20185-73N/A-31N/A
6/30/20186-125N/A-31N/A
3/31/20184-133N/A-33N/A
12/31/20173-20N/A-31N/A
9/30/2017447N/A-34N/A
6/30/2017364N/A-35N/A
3/31/20174100N/A-36N/A
12/31/2016634N/A-42N/A
9/30/2016625N/A-47N/A
6/30/20167-20N/A-50N/A
3/31/20168-54N/A-50N/A
12/31/20157-47N/A-45N/A
9/30/20157-45N/A-40N/A
6/30/20156-39N/A-37N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: LCTX is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (3.5%).

Earnings vs Market: LCTX is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: LCTX is expected to become profitable in the next 3 years.

Revenue vs Market: LCTX's revenue (62% per year) is forecast to grow faster than the US market (11.9% per year).

High Growth Revenue: LCTX's revenue (62% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if LCTX's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/01 10:30
End of Day Share Price 2026/05/29 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Lineage Cell Therapeutics, Inc. is covered by 12 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jack AllenBaird
Mayank MamtaniB. Riley Securities, Inc.
John NewmanCanaccord Genuity